S
Spruce Biosciences, Inc. (SPRB)
NCM – Real vaqt narxi. Valyuta: USD
63.04
-6.07 (-8.78%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
63.00
-0.04 (-0.06%)
Bozordan keyin: Mar 27, 2026, 4:33 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
63.04
-6.07 (-8.78%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
63.00
-0.04 (-0.06%)
Bozordan keyin: Mar 27, 2026, 4:33 PM EDT
Spruce Biosciences, Inc. nevrologik kasalliklar uchun yangi davolash usullarini ishlab chiqish va tijoratlashtirishga qaratilgan biofarmatsevtika kompaniyasidir. Kompaniya Sanfilippo sindromi B turi bilan og'rigan bemorlar uchun enzim o'rnini bosuvchi terapiya bo'lgan rekombinant inson alfa-N-asetilglyukozaminidazadan iborat fuzion oqsil TA-ERTni ishlab chiqadi. Shuningdek, u anhedoniya, vazn o'zgarishlari va uyqu rejimining o'zgarishi kabi kognitiv-affektiv va somatik o'zgarishlar bilan birga depressiv kayfiyat bilan tavsiflangan og'ir nogironlikka olib keladigan ruhiy kasallikni davolash uchun Tildacerfontni ishlab chiqadi. Bundan tashqari, kompaniya hech qanday davosi bo'lmagan surunkali va potentsial hayot uchun xavfli kam uchraydigan kasallik bo'lgan tug'ma buyrak usti bezlari giperplaziyasi (CAH)ni davolash uchun SPR202ni ishlab chiqadi. Kompaniya turli farmatsevtika birikmalarini tadqiq qilish, ishlab chiqish va tijoratlashtirish bo'yicha Eli Lilly and Company bilan litsenzion kelishuvga ega. Shuningdek, u Yaponiyada CAHni davolash uchun Tildacerfontni ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha Kaken Pharmaceutical Co. Ltd. bilan hamkorlik va litsenzion kelishuvga ega. Spruce Biosciences, Inc. 2014 yilda ro'yxatga olingan va uning shtab-kvartirasi Kaliforniyaning Janubiy San-Frantsiskoda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Daven Mody Pharm.D. | Senior Vice President of Regulatory & Quality |
| Dr. Javier Szwarcberg M.D., M.P.H. | CEO & Director |
| Dr. Kirk Ways M.D., Ph.D. | Chief Medical Officer & Director |
| Mr. Bruno Gagnon BPHARM, M.Sc. | Senior Vice President of Clinical Development Operations |
| Mr. Corwin Dale Hooks | Chief Commercial Officer |
| Mr. Michael G. Grey | Executive Chairman |
| Mr. Samir M. Gharib CPA, M.B.A. | President & CFO |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-20 | 8-K | sprb-20260316.htm |
| 2026-03-09 | 10-K | sprb-20251231.htm |
| 2026-01-08 | 8-K | sprb-20260107.htm |
| 2025-12-15 | 8-K | sprb-20251211.htm |
| 2025-12-12 | 8-K | sprb-20251211.htm |
| 2025-11-10 | 8-K | sprb-20251110.htm |
| 2025-10-29 | S-3 | sprb-20251029.htm |
| 2025-10-17 | 8-K | sprb-20251015.htm |
| 2025-10-08 | 8-K | d36248d8k.htm |
| 2025-08-14 | 10-Q | sprb-20250630.htm |